Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [2] - The company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, which has broad therapeutic potential [2] - Eledon is conducting preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) [2] Upcoming Event - Steve Perrin, Ph.D., President and Chief Scientific Officer of Eledon, will participate in a plenary session at the 18 Congress of the International Xenotransplantation Association (IXA) from September 30–October 3, 2025, in Geneva, Switzerland [1] - The plenary session will focus on immunosuppression, immune monitoring, and anti-CD154 pathway blockade, with a specific lecture titled "201.2 Anti-CD154 Pathway Blockade" scheduled for October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET [1]